Crossmark

Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study

Crossref DOI link: https://doi.org/10.1186/s13643-021-01838-8

Published Online: 2021-11-01

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jimenez-Mora, Mario A.

Varela, Andrea Ramírez

Meneses-Echavez, Jose F. https://orcid.org/0000-0003-4312-6909
Bidonde, Julia

Angarita-Fonseca, Adriana

Siemieniuk, Reed A. C.

Zeraatkar, Dena

Bartoszko, Jessica J.

Brignardello-Petersen, Romina

Honarmand, Kimia

Rochwerg, Bram

Guyatt, Gordon

Yepes-Nuñez, Juan José
License Information

Text and Data Mining valid from 2021-11-01

Version of Record valid from 2021-11-01
More Information

Article History

Received: 11 November 2020

Accepted: 13 October 2021

First Online: 1 November 2021

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below